INFECTIOUS DISEASES AND VACCINES, EXCLUDING AIDS/HIV
Infectious / Vaccines

Division of Research Principal Investigators: Steve Sidney, MD
Primary Source of Funding: National Institute of Neurological Disorders and Stroke
Description: Title defines study.

Division of Research Principal Investigators: Steven Black, MD; Henry R. Shinefield, MD
Primary Source of Funding: Centers for Disease Control and Prevention
Total Project Period: September 1995 – September 2008
Description: This project expands and maintains a large linked database that constitutes a comprehensive medical events file for an annual birth cohort of 28,000 children within Kaiser Permanente, Northern California, and assesses the rates of occurrence of medical events after immunization in children and adolescents.

Division of Research Principal Investigator: Steven Black, MD
Primary Source of Funding: Centers for Disease Control and Prevention
Total Project Period: September 2001 – September 2012
Description: The CISA center is a consortium headed by Kaiser Permanente, Northern California, including Stanford University and Vanderbilt University. The goal of these centers is to improve understanding of clinically significant adverse events following immunization. Through clinical assessments and specialized laboratory investigations, genetic or other risk factors that predispose to adverse events will be determined.

Division of Research Principal Investigator: Steven Black, MD
Primary Source of Funding: National Institute of Allergy and Infectious Diseases
Total Project Period: November 2001 – October 2006
Description: Using the clinical trials capabilities of Kaiser Permanente, Northern California, these studies enroll subjects and provide services for the conduct of government-funded Phase II and IV clinical trials in infants, children, and adults, and use the laboratory expertise of investigators at Stanford and Vanderbilt Universities to measure the immune responses to vaccines.

Division of Research Principal Investigator: T. R. Levin, MD
Primary Source of Funding: Centers for Disease Control and Prevention
Total Project Period: July 2002 – July 2004
Description: The aim of this study is to evaluate risk factors for the transmission of hepatitis C among stable heterosexual partners.

Principal Investigator: Steve Black, MD
Funding Agent: Aventis Pasteur, Inc
Description: The purpose of this study is to evaluate variability in prebooster dose concentrations of antibody with different Hib vaccines. Since higher antibody levels are correlated with increased protection, these differences, if they exist, could lead to changes in recommendations for vaccine use.

Division of Research Principal Investigator: Michael Silverberg, PhD
Primary Source of Funding: SmithKline Beecham Corp
Description: This is a retrospective cohort study to quantify changes over time in the prevalence and management of dyslipidemia among HIV-infected patients; it will also measure the effectiveness of lipid lowering therapy in this population compared to those without HIV infection.

Division of Research Principal Investigator: Steve Black, MD
Primary Source of Funding: Centers for Disease Control and Prevention
Total Project Period: February 2003 – October 2003
Description: Title describes study.

Division of Research Principal Investigator: Theodore Levin, MD
Primary Source of Funding: Merck & Co, Inc.
Description: The goal of this observational study is to evaluate the effect of statin use on the natural history of liver disease.

Primary Source of Funding: Centers for Disease Control and Prevention
Total Project Period: May 1998 – December 2004
Division of Research Principal Investigator: M. Michele Manos, PhD, MPH
Description: This study aims to: determine the incidence of physician-diagnosed chronic liver disease in a defined geographic area; determine the relative contribution of chronic HBV, HCV, and other etiologies to the burden of disease; determine the influence of etiologic agent(s) and other factors on morbidity and mortality; monitor the incidence of and mortality from chronic liver disease in a defined geographic area over time.